ZLOADR
One of the world’s leading crypto publishing platforms, Zloadr, has announced that it is launching a new online cryptocurrency converter calculator , adding to its existing range of digital tools. The calculator acts as an automated world currency and cryptocurrency converter, enabling users of the platform to convert a wide range of global, Government-issued fiat currencies to the value of different cryptocurrencies, and vice versa – quickly and easily. The calculator is expected to rival existing online conversion tools.
Early statistics indicate that bitcoin (BTC) is among one of the most commonly converted cryptocurrencies right now, in line with the coin’s position at the top of the market capitalisation leaderboard. Bitcoin appears to be most frequently considered alongside the United States Dollar (USD) and British Pound (GBP). Ethereum (ETH), second by market cap, is also shown to be popular with users.
Zloadr’s new currency calculator is understood to be one of the most comprehensive online converters available to web users today, not only covering fiat currencies from the Afghanistan Afghani (AFN) to the Zimbabwean Dollar (ZWL), but also including cryptocurrencies such as bitcoin, litecoin (LTC), ethereum, ethereum classic (ETC), ripple (XRP), and dash (DASH). Zloadr, which was founded in 2015, conducted an initial coin offering (ICO) of its own token last year, prior to the full launch of the publishing platform.
The launch of Zloadr’s digital conversion tool follows the platform’s recent expansion into international markets, and forms the latest in a long line of exciting announcements. Following on from a partnership with The Guardian newspaper in Nigeria, and with the beginnings of a new associated smart contract project, DocTailor, Zloadr has also recently announced that it will shortly re-launch select features and functions of its website, making these sections available in multiple languages, including Spanish, German, Portuguese, Chinese, Japanese, Indonesian, and Russian.
At a time when interest in both cryptocurrency and blockchain technology is expanding out of major markets such as the United Kingdom and United States, Zloadr is demonstrating a strong ability to maintain not only its relevance, but also its dedication to its international user base, through a range of multi language online tools as well as the new currency and cryptocurrency converter. Zloadr’s Currency Calculator is expected to be among the features that will offer different language options for users, alongside the platform’s ICO Calendar and its real time cryptocurrency market capitalisations listing.
About Zloadr
Zloadr is the first viral digital news publishing platform on the blockchain powered by influencers. Zloadr distributes content and grows income for content creators around the world.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180201006029/en/
Contact:
Zloadr Limited
Dominic Brown
+44 7951 811 718
Chief
Operation Officer
dominic@zloadr.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom